ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Press Ganey Appoints Avanish Mishra, Ph.D., as President, Life Sciences

Veteran executive to lead Press Ganey’s growth and innovation across the life sciences sector

Press Ganey, the leading provider of experience measurement, analytics, and insights for health systems and health plans, today announced the appointment of Dr. Avanish Mishra as President, Life Sciences. Reporting to Patrick T. Ryan, Chairman and CEO of Press Ganey Forsta, Dr. Mishra will drive the next phase of innovation and expansion for the company’s life sciences business.

A globally accomplished executive, Dr. Mishra brings deep scientific and commercial experience, holding senior roles at Thermo Fisher Scientific, Gilead, and Pfizer. In his most recent role as General Manager of Real World Data at Thermo Fisher, he oversaw critical high-growth initiatives, including the company’s global COVID-19 response.

As President of Life Sciences, Dr. Mishra will spearhead Press Ganey’s work to redefine how life sciences companies engage with patients and providers across the product lifecycle—from clinical development through commercial delivery. By harnessing the company’s unmatched expertise in human experience, advanced analytics, and technology, Dr. Mishra will lead efforts to unlock new levels of customer insight, accelerate decision-making, and drive operational efficiency across the life sciences ecosystem.

“Avanish is a proven innovator with both the scientific depth and commercial expertise to scale products that solve complex challenges,” Ryan said. “His appointment signals a transformational moment for our company and our partners in life sciences. With Avanish at the helm, we will accelerate the shift toward more personalized, insight-driven engagement strategies that put people—patients, providers, and caregivers—at the center of innovation.”

Throughout his 20+ year career, Dr. Mishra has championed business transformation across the U.S., Japan, and APAC markets. While at Pfizer, he scaled a joint venture from inception to over $400 million in revenue in just three years. He holds a Ph.D. in Pharmacy Administration and has authored numerous publications widely cited in the scientific community.

About Press Ganey:

P
ress Ganey partners with healthcare providers and health plans to improve the experiences of their patients and workforce by marrying data with unparalleled technology and expertise. Our HX platform unites and enlivens disparate data, enabling clients to gather, analyze, visualize, and act on key insights to retain employees and ensure the care journey is accessible, safe, equitable, and patient-centered. We are the trusted partner to over 41,000 healthcare provider organizations globally and 85% of health plans in the United States. Press Ganey is a PG Forsta company.

About PG Forsta

PG Forsta is the leading provider of experience technology, data analytics, and insights that help companies better understand and serve their customers, employees, and stakeholders. PG Forsta powers the Human Experience (HX) Platform – a comprehensive experience and research technology platform that brings together CX (Customer Experience), Employee Experience (EX), Patient Experience (PX) and Market Research. It serves more than 43,000 clients globally across healthcare, financial services, hospitality, market research, professional services, retail, and technology.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.